Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal



Scientific publications

LIST OF PUBLICATIONS BY PHARMATEST

PUBLISHED SCIENTIFIC PAPERS INCLUDING RESULTS FROM STUDIES PERFORMED IN PHARMATEST

  1. Potential of Targeting Bone Metastases with Immunotherapies. Novel Approaches in Cancer Study doi: 10.31031/NACS.2019.03.000561.
  2. The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. International Journal of Molecular Sciences.
  3. Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone. Journal of Immunology Research doi: 10.1155/2019/4260987.

  4. Characterization a model of prostatic diseases and obstructive voiding induced by sex hormone imbalance in the Wistar and Noble rats. Translational Andrology and Urology doi: 10.21037/tau.2019.02.03.
  5. Novel and Conventional Preclinical Models to Investigate Bone Metastasis. Curr Mol Bio Rep 5:48–54.

  6. Chronic nonbacterial prostate inflammation in a rat model is associated with changes of gut microbiota that can be modified with a galactoglucomannan‐rich hemicellulose extract in diet. Wiley doi: 10.1111/bju.14553.
  7. Antitumor Activity of Novel Bone-seeking, α-emitting 224Ra-solution in a Breast Cancer Skeletal Metastases Model. ANTICANCER RESEARCH 38(4): 1947-1955.
  8. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 23(15):4335-46.
  9. Galactoglucomannan-rich hemicellulose extract from Norway spruce (Picea abies) exerts beneficial effects on chronic prostatic inflammation and lower urinary tract symptoms in vivo. Int J Biol Macromol 101 222-229.

  10. Intravesical treatment with cis-urocanic acid improves bladder function in rat model of acute bladder inflammation. Neurourol Urodyn 35(7):786-91.
  11. Importance of microenvironment in preclinical models of breast and prostate cancer. World J Pharmacol 4(1):47-57.
  12. Effects of afala and antiestrogen ICI 182,780 in the model of hormone-dependent prostate inflammation. Bull Exp Biol Med 156(6):807-9.

  13. Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis. J Natl Cancer Inst 105(12):908-916.
  14. Expression of metastasin S100A4 is essential for bone resorption and regulates osteoclast function.  Biochim Biophys Acta 1833(12):2653-63.
  15. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Cancer Res 10(5):597-604.
  16. Improved statistical modeling of tumor growth and treatment effect in preclinical animal studies with highly heterogeneous responses in vivo. Clin Cancer Res 18(16):4385-96.
  17. The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo. Osteoporos Int (2011) 22:2887–2893.
  18. ZP2307, a novel, cyclic PTH(1-17) analog that augments bone mass in ovariectomized rats. Bone 48:1319-1327.
  19. Models and screening assays for drug development in osteoporosis. Expert Opin Drug Discov 5:1163-1174.
  20. Effects of diet-induced obesity and voluntary wheel running on bone properties in young male C57BL/6J mice. Calcif Tissue Int 86:411-419.
  21. Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts. BMC Cancer.30;10:596.
  22. Improved methods for testing antiresorptive compounds in human osteoclast cultures. J Bone Miner Metab 27:105-109.
  23. Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. BMC Cancer. 12;9:362.
  24. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 82:108-115.
  25. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcif Tissue Int 82:155-161.
  26. Effects of bioactive peptide, valyl-prolyl-proline (VPP), and lactobacillus helveticus fermented milk containing VPP on bone loss in ovariectomized rats. Ann Nutr Metab 51:65-74.

SELECTED OTHER PUBLICATIONS BY PHARMATEST STAFF

  1. Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro. Bone 44:717-728.
  2. Fispemifene (Z-2-{2-[4-(4 Chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol), a novel selective estrogen receptor modulator, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis. J Pharmacol Exp Ther. 327:58-67.
  3. Overexpression of human hydroxysteroid (17beta) dehydrogenase 2 induces disturbance in skeletal development in young male mice. J Bone Miner Res. 23(8):1217-26.
  4. Prostatic inflammation and obstructive voiding in the adult Noble rat: Impact of the testosterone to estradiol ratio in serum. Prostate, 68:1296-1306.
  5. Histopathological evidence for an association of inflammation with ductal PIN-like lesion but not with ductal adenocarcinoma in the prostate of the Noble rat. Prostate, 68:728-739.
  6. Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 8:315-323. (Review)
  7. Tartrate-resistant acid phosphatase 5b as a marker of bone resorption (Review). Clin Lab 52:499-509.
  8. Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. Arthritis Rheum 52:3713-3717
  9. Estrogen responsiveness of bone formation in vitro and altered bone phenotype in aged estrogen receptor-alpha-deficient male and female mice. Eur J Endocrinol. 152(2):301-14.
  10. Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption. Biochem Biophys Res Commun. 7;335(4):1095-101.
  11. Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K. Bone 36:854-865.
  12. Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover. J Bone Miner Res 20:1804-1812.
  13. Impaired bone resorption in cathepsin K deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36:159-172.
  14. Properties and expression of human tartrateresistant acid phosphatase isoform 5a by monocyte-derived cells. J Leukoc Biol. 77(2):209-18.
  15. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386-393.
  16. Skeletal changes in transgenic male mice expressing human cytochrome p450 aromatase. J Bone Miner Res.19(8):1320-8.
  17. Abnormal craniofacial development and expression patterns of extracellular matrix components in transgenic Del1 mice harboring a deletion mutation in the type II collagen gene. Orthod Craniofac Res 7:216-226.
  18. Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis. Ann Rheum Dis 63:649-655.
  19. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res. 19(9):1432-40.
  20. A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum. J Bone Miner Res. 18(1):134-9.
  21. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 16:1444-1452.
  22. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 141(2):809-20.
  23. Tartrate-Resistant Acid Phosphatase 5b, a Novel Serum Marker of Bone Resorption. J Bone Miner Res 15:1337-1345.
  24. Alteration in the mechanical competence and structural properties in the femoral neck and vertebrae of ovariectomized rats. J Bone Miner Res.14(4):616-23.
  25. Effect of clodronate treatment on established bone loss in ovariectomized rats. Bone. 23(4):333-42.
  26. Comparison of three-point bending test and peripheral quantitative computed tomography analysis in the evaluation of the strength of mouse femur and tibia. Bone 23:155-161.
  27. Clodronate prevents osteopenia and loss of trabecular connectivity in estrogen-deficient rats. J Bone Miner Res 13(2):287-96
  28. The effect of orally administered clodronate on bone mineral density and bone geometry in ovariectomized rats. J Pharmacol Exp Ther. 284(1):312-6
  29. Clodronate prevents bone loss in aged ovariectomized rats. Calcif Tissue Int. 61(2):151-7.
  30. Ovariectomy-induced bone loss can be affected by different intensities of treadmill running exercise in rats. Calcif Tissue Int. 60(5):441-8.
  31. Long-term effects of ovariectomy on the mechanical properties and chemical composition of rat bone. Bone 20(3):207-12
  32. Exercise can provide protection against bone loss and prevent the decrease in mechanical strength of femoral neck in ovariectomized rats. J Bone Miner Res. 9(10):1559-64.
  33. Effect of running exercise on the bone loss induced by orchidectomy in the rat. Calcif Tissue Int. 55(1):33-7.
  34. The mechanical strength of bone in different rat models of experimental osteoporosis. Bone 15:523-532.
  35. The effect of training on the recovery from immobilization-induced bone loss in rats. Acta Physiol Scand. 145(4):407-11.
  36. Effect of exercise on osteoporosis induced by ovariectomy in rats. Calcif Tissue Int. 49 Suppl:S80.